Key Points
- CEO Phillip Chan bought 200,000 Cytosorbents shares at an average price of $0.35, a $70,000 transaction that increased his position by 11.47% to 1,944,432 shares.
- Cytosorbents reported quarterly revenue of $9.63 million and a loss of $0.07 per share, beating analysts’ estimates, but remains unprofitable with a negative net margin of 48.94%.
- Analyst sentiment is mixed, with one Buy, one Hold and one Sell rating; the stock carries a consensus Hold rating despite a stated price target of $107.50, while institutional investors own 32.87% of shares.
Cytosorbents Corporation (NASDAQ:CTSO - Get Free Report) CEO Phillip Chan bought 200,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were acquired at an average cost of $0.35 per share, with a total value of $70,000.00. Following the completion of the purchase, the chief executive officer owned 1,944,432 shares in the company, valued at $680,551.20. This represents a 11.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Cytosorbents Stock Performance
Shares of CTSO opened at $6.33 on Thursday. The firm has a market cap of $19.95 million, a P/E ratio of -1.09 and a beta of 1.34. Cytosorbents Corporation has a twelve month low of $6.00 and a twelve month high of $20.40. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.50 and a current ratio of 0.66. The firm's 50 day moving average price is $7.35 and its two-hundred day moving average price is $10.04.
Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.73. The business had revenue of $9.63 million for the quarter, compared to analyst estimates of $9.38 million. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. On average, analysts forecast that Cytosorbents Corporation will post -4.4 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of CTSO. Avenir Corp boosted its holdings in shares of Cytosorbents by 2.9% in the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company's stock valued at $3,343,000 after buying an additional 147,261 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in Cytosorbents during the third quarter worth $161,000. Citadel Advisors LLC raised its position in Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company's stock worth $61,000 after acquiring an additional 36,790 shares in the last quarter. Vanguard Group Inc. lifted its stake in Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company's stock valued at $2,059,000 after acquiring an additional 79,535 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock valued at $63,000 after acquiring an additional 37,519 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cytosorbents in a research report on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Cytosorbents has an average rating of "Hold" and a consensus price target of $107.50.
Read Our Latest Report on Cytosorbents
Cytosorbents Company Profile
(
Get Free Report)
Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company's flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient's blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.
CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
